Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR plus zanubrutinib in treatment-naive CLL/SLL
ChiCTR2000041532Phase 4Recruiting
- Sponsor
- Pukou Chronic Lymphocytic Leukemia Center
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib, rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Pukou Chronic Lymphocytic Leukemia Center. Primary endpoints: Bone marrow undetectable minimal residual disease rate and Adverse event rate. Started Feb 2021; status: recruiting.
02
Drugs
zanubrutinibrituximabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2000041532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041532.